Madrigal Pharmaceuticals (MDGL) Receiving Somewhat Positive Press Coverage, Analysis Shows

Media stories about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.6663037046805 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) opened at 17.96 on Wednesday. The company has a 50-day moving average of $16.34 and a 200 day moving average of $15.82. Madrigal Pharmaceuticals has a 12-month low of $9.85 and a 12-month high of $18.35. The stock’s market capitalization is $224.41 million.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.09). Analysts predict that Madrigal Pharmaceuticals will post ($2.57) earnings per share for the current year.

Separately, ValuEngine raised shares of Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 19th.

TRADEMARK VIOLATION WARNING: “Madrigal Pharmaceuticals (MDGL) Receiving Somewhat Positive Press Coverage, Analysis Shows” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/09/13/madrigal-pharmaceuticals-mdgl-receiving-somewhat-positive-press-coverage-analysis-shows.html.

In related news, Director Richard S. Levy purchased 3,550 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average cost of $15.88 per share, for a total transaction of $56,374.00. Following the completion of the transaction, the director now owns 900 shares in the company, valued at $14,292. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard S. Levy purchased 2,000 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 23rd. The shares were bought at an average price of $16.12 per share, with a total value of $32,240.00. Following the completion of the transaction, the director now owns 7,200 shares of the company’s stock, valued at approximately $116,064. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 9,100 shares of company stock valued at $145,840. 66.40% of the stock is owned by company insiders.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Insider Buying and Selling by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply